PAINS: Relevance to tool compound discovery and fragment-based screening

Jonathan Bayldon Baell, Lori Ferrins, Hendrik Falk, George Nikolakopoulos

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Pan assay interference compounds (PAINS) are readily discovered in any bioassay and can appear to give selective and optimisable hits. The most common PAINS can be readily recognised by their structure. However, there are compounds that closely resemble PAINS that are not specifically recognised by the PAINS filters. In addition, highly reactive compounds are not encoded for in the PAINS filters because they were excluded from the high-throughput screening (HTS) library used to develop the filters and so were never present to provide indicting data. A compounding complication in the area is that very occasionally a PAINS compound may serve as a viable starting point for progression. Despite such an occasional example, the literature is littered with an overwhelming number of examples of compounds that fail to progress and were probably not optimisable in the first place, nor useful tool compounds. Thus it is with great caution and diligence that compounds possessing a known PAINS core should be progressed through to medicinal chemistry optimisation, if at all, as the chances are very high that the hits will be found to be non-progressable, often after a significant waste of resources.
Original languageEnglish
Pages (from-to)1483 - 1494
Number of pages12
JournalAustralian Journal of Chemistry
Volume66
Issue number12
DOIs
Publication statusPublished - 2013

Cite this

Baell, Jonathan Bayldon ; Ferrins, Lori ; Falk, Hendrik ; Nikolakopoulos, George. / PAINS: Relevance to tool compound discovery and fragment-based screening. In: Australian Journal of Chemistry. 2013 ; Vol. 66, No. 12. pp. 1483 - 1494.
@article{e3c0ec0c106045b69760c8b2bcda43f4,
title = "PAINS: Relevance to tool compound discovery and fragment-based screening",
abstract = "Pan assay interference compounds (PAINS) are readily discovered in any bioassay and can appear to give selective and optimisable hits. The most common PAINS can be readily recognised by their structure. However, there are compounds that closely resemble PAINS that are not specifically recognised by the PAINS filters. In addition, highly reactive compounds are not encoded for in the PAINS filters because they were excluded from the high-throughput screening (HTS) library used to develop the filters and so were never present to provide indicting data. A compounding complication in the area is that very occasionally a PAINS compound may serve as a viable starting point for progression. Despite such an occasional example, the literature is littered with an overwhelming number of examples of compounds that fail to progress and were probably not optimisable in the first place, nor useful tool compounds. Thus it is with great caution and diligence that compounds possessing a known PAINS core should be progressed through to medicinal chemistry optimisation, if at all, as the chances are very high that the hits will be found to be non-progressable, often after a significant waste of resources.",
author = "Baell, {Jonathan Bayldon} and Lori Ferrins and Hendrik Falk and George Nikolakopoulos",
year = "2013",
doi = "10.1071/CH13551",
language = "English",
volume = "66",
pages = "1483 -- 1494",
journal = "Australian Journal of Chemistry",
issn = "0004-9425",
publisher = "CSIRO Publishing",
number = "12",

}

PAINS: Relevance to tool compound discovery and fragment-based screening. / Baell, Jonathan Bayldon; Ferrins, Lori; Falk, Hendrik; Nikolakopoulos, George.

In: Australian Journal of Chemistry, Vol. 66, No. 12, 2013, p. 1483 - 1494.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - PAINS: Relevance to tool compound discovery and fragment-based screening

AU - Baell, Jonathan Bayldon

AU - Ferrins, Lori

AU - Falk, Hendrik

AU - Nikolakopoulos, George

PY - 2013

Y1 - 2013

N2 - Pan assay interference compounds (PAINS) are readily discovered in any bioassay and can appear to give selective and optimisable hits. The most common PAINS can be readily recognised by their structure. However, there are compounds that closely resemble PAINS that are not specifically recognised by the PAINS filters. In addition, highly reactive compounds are not encoded for in the PAINS filters because they were excluded from the high-throughput screening (HTS) library used to develop the filters and so were never present to provide indicting data. A compounding complication in the area is that very occasionally a PAINS compound may serve as a viable starting point for progression. Despite such an occasional example, the literature is littered with an overwhelming number of examples of compounds that fail to progress and were probably not optimisable in the first place, nor useful tool compounds. Thus it is with great caution and diligence that compounds possessing a known PAINS core should be progressed through to medicinal chemistry optimisation, if at all, as the chances are very high that the hits will be found to be non-progressable, often after a significant waste of resources.

AB - Pan assay interference compounds (PAINS) are readily discovered in any bioassay and can appear to give selective and optimisable hits. The most common PAINS can be readily recognised by their structure. However, there are compounds that closely resemble PAINS that are not specifically recognised by the PAINS filters. In addition, highly reactive compounds are not encoded for in the PAINS filters because they were excluded from the high-throughput screening (HTS) library used to develop the filters and so were never present to provide indicting data. A compounding complication in the area is that very occasionally a PAINS compound may serve as a viable starting point for progression. Despite such an occasional example, the literature is littered with an overwhelming number of examples of compounds that fail to progress and were probably not optimisable in the first place, nor useful tool compounds. Thus it is with great caution and diligence that compounds possessing a known PAINS core should be progressed through to medicinal chemistry optimisation, if at all, as the chances are very high that the hits will be found to be non-progressable, often after a significant waste of resources.

UR - http://www.publish.csiro.au/?paper=CH13551

U2 - 10.1071/CH13551

DO - 10.1071/CH13551

M3 - Article

VL - 66

SP - 1483

EP - 1494

JO - Australian Journal of Chemistry

JF - Australian Journal of Chemistry

SN - 0004-9425

IS - 12

ER -